Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

References

• Kearney PM Whelton M Reynolds K Muntner P Whelton PK He J Global burden of hypertension: analysis of worldwide data Lancet 2005 365 9455 217 223 15652604
   PubMed Web of Science ®Google Scholar
• Choi KM Park HS Han JH Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001 J Hypertens 2006 24 8 1515 1521 16877953
   PubMed Web of Science ®Google Scholar
• Ezzati M Lopez AD Rodgers A Vander Hoorn S Murray CJ Selected major risk factors and global and regional burden of disease Lancet 2002 360 9343 1347 1360 12423980
   PubMed Web of Science ®Google Scholar
• Chobanian AV Bakris GL Black HR Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 2003 42 6 1206 1252 14656957
   PubMed Web of Science ®Google Scholar
• Mancia G De Backer G Dominiczak A 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 2007 28 12 1462 1536 17562668
   PubMed Web of Science ®Google Scholar
• Izuhara Y Nangaku M Inagi R Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering J Am Soc Nephrol 2005 16 12 3631 3641 16236804
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, Food and Drug Administration Guidance for Industry; Pharmacokinetics in Patients with Impaired Renal Function – Study Design, Data Analysis, and Impact on Dosing and Labeling Rockville, MD US Food and Drug Administration, Drug Information Branch 2010 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf Accessed June 3, 2014
   Google Scholar
• Chi YH Lee H Paik SH Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects Am J Cardiovasc Drugs 2011 11 5 335 346 21910510
   PubMed Web of Science ®Google Scholar
• Levey AS Bosch JP Lewis JB Greene T Rogers N Roth D A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 1999 130 6 461 470 10075613
   PubMed Web of Science ®Google Scholar
• Yi S Kim JW Kim TE Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers Int J Clin Pharmacol Ther 2011 49 5 321 327 21543035
   PubMed Web of Science ®Google Scholar
• Shin KH Kim TE Kim SE The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers J Cardiovasc Pharmacol 2011 58 5 492 499 21765368
   PubMed Web of Science ®Google Scholar
• Lee H Yang HM Lee HY Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies Clin Ther 2012 34 6 1273 1289 22608107
   PubMed Web of Science ®Google Scholar
• Yi S Kim TE Yoon SH Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers J Cardiovasc Pharmacol 2011 57 6 682 689 21394036
   PubMed Web of Science ®Google Scholar
• Kim JW Yi S Kim TE Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin J Clin Pharmacol 2013 53 1 75 81 23400746
   PubMed Web of Science ®Google Scholar
• Nolin TD Naud J Leblond FA Pichette V Emerging evidence of the impact of kidney disease on drug metabolism and transport Clin Pharmacol Ther 2008 83 6 898 903 18388866
   PubMed Web of Science ®Google Scholar
• Dreisbach AW Lertora JJ The effect of chronic renal failure on drug metabolism and transport Expert Opin Drug Metab Toxicol 2008 4 8 1065 1074 18680441
   PubMed Web of Science ®Google Scholar
• Sica DA Lo MW Shaw WC The pharmacokinetics of losartan in renal insufficiency J Hypertens Suppl 1995 13 1 S49 S52 18800456
   PubMedGoogle Scholar
• Cozaar^® (losartan potassium tablets) [package insert] Whitehouse Station, NJ Merck & Co, Inc 2003
   Google Scholar
• Prasad P Mangat S Choi L Effect of renal function on the pharmacokinetics of valsartan Clin Drug Invest 1997 13 4 207 214
   Web of Science ®Google Scholar
• Diovan (valsartan tablets) [package insert] East Hanover, NJ Novartis Pharmaceuticals Corp 1996
   Google Scholar